论文部分内容阅读
目的 研究胆囊癌和胆管癌组织中微血管 (microvessel,MV)计数和血管内皮生长因子(vascularendothelialgrowthfactor,VEGF)、碱性成纤维细胞生长因子 (basicfibroblastgrowthfactor,bFGF)表达及其意义。方法 以ABC免疫组化法对 40例胆囊癌和 42例胆管癌组织常规石蜡包埋切片分别检测MV、VEGF和bFGF。结果 40例胆囊癌MV定量为 (6 6± 2 7)个 /HP ,VEGF、bFGF阳性率分别5 0 % (2 0 / 40 )和 5 3% (2 1/ 40 ) ;42例胆管癌MV定量为 (75± 19)个 /HP ,VEGF、bFGF阳性率分别为 5 5 %(2 3/ 42 )和 5 7% (2 4/ 42 )。高分化和未转移胆囊癌MV定量及VEGF、bFGF阳性率明显低于低分化腺癌〔(5 0± 2 4)vs.(89± 2 6 ) ,P <0 0 1;39%vs.6 7% ,P >0 0 5 ;39%vs.76 % ,P <0 0 5〕和转移癌〔(4 8± 9)vs.(86± 30 ) ,P <0 0 1;32 %vs .72 % ,P <0 0 5 ;36 %vs.72 % ,P <0 0 5〕 ;高分化和未转移胆管癌MV定量及VEGF、bFGF阳性率明显低于未分化癌〔(6 6± 15 )vs .(86± 2 3) ,P <0 0 5 ;41%vs.86 % ,P <0 0 5 ;35 %vs .76 % ,P <0 0 5〕和转移癌〔(6 3± 17)vs.(90± 15 ) ,P <0 0 1;40 %vs.76 % ,P <0 0 5 ,44 %vs .76 % ,P <0 0 5〕。VEGF(+ )、或bFGF(+ )或VEGF(+ )bFGF(+ )的胆囊癌和胆管癌MV定量明显
Objective To study the expression of microvessel (MV), vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) in gallbladder carcinoma and cholangiocarcinoma. Methods ABC immunohistochemistry was used to detect MV, VEGF and bFGF in paraffin-embedded sections of 40 cases of gallbladder carcinoma and 42 cases of cholangiocarcinoma. Results The quantification of MV in 40 cases of gallbladder carcinoma was (6 6 ± 2 7)/HP. The positive rates of VEGF and bFGF were 50% (2 0 / 40) and 5 3% (2 1 / 40) respectively; 42 cases of cholangiocarcinoma MV The quantification was (75±19)/HP, and the positive rates of VEGF and bFGF were 55% (23/42) and 57% (24/42), respectively. The positive rates of MV and VEGF and bFGF were significantly lower in well-differentiated and non-metastatic gallbladder carcinomas than in poorly differentiated adenocarcinomas ((50±24) vs. (89±26), P<0.01; 39% vs. 6 7%, P >0 05; 39% vs 76%, P <0 0 5) and metastatic carcinoma ((48±9) vs. (86±30), P <0 01; 32% vs. 72%, P <0 05; 36% vs. 72%, P <0 05; MVD and VEGF, bFGF positive rate in well-differentiated and non-metastatic cholangiocarcinoma were significantly lower than those in undifferentiated carcinoma (6 6 ± 15 ) vs. (86 ± 2 3), P <0 0 5; 41% vs. 86%, P <0 0 5; 35% vs. 76%, P <0 0 5] and metastatic carcinoma ((6 3 ±) 17) vs. (90 ± 15), P <0 0 1; 40% vs. 76%, P <0 0 5, 44% vs. 76%, P <0 0 5]. VEGF (+) or bFGF (+) or VEGF (+) bFGF (+) quantification of MV in gallbladder and cholangiocarcinoma